About Event

About The B & T Cell-Mediated Autoimmune Disease Drug Development Summit

The 3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit is your definitive meeting exclusively focusing on the common challenges across the B & T cell space including harnessing monoclonal antibodies for B & T cell immune checkpoints, combination approaches for T-cell co-stimulation via immune checkpoints, targeting autoantibodies via FcRn inhibition of plasma cells and PROTAC/degrader approaches, and many more.

As we look to the future of drug development for autoimmune diseases, this is your opportunity to join 80+ key leaders and decision-makers, at the cutting edge of science accelerating the development of successful drug modalities.

Be a part of the movement! Join this unmissable 3-day summit to get access to next-generation research and connect with like-minded peers accelerating the drug development of B & T cell-mediated autoimmune diseases with an improved therapeutic potential. Together we can bring more effective drugs to a large population of patients in need.

Top 5 Takeaways You Cannot Afford to Miss:

5254_T_B-Cell_Mediated_Autoimmune_DDD (4)

Gain a comparison of the landscape of B & T cell-mediated autoimmune diseases with Gossamer Bio, NYSCF and Immunic

5254_T_B-Cell_Mediated_Autoimmune_DDD (4)

Explore the latest developments of the leading drug targets and therapeutics with COUR Pharmaceuticals, Eledon and Cabaletta Bio

5254_T_B-Cell_Mediated_Autoimmune_DDD (4)

Hear from leaders in the B&T cell and drug development fields, including Kyverna, Provention Bio and Eli & Lilly Co

5254_T_B-Cell_Mediated_Autoimmune_DDD (4)

Leverage antigen-specific & degrader approaches to target autoimmune diseases with Kymera Therapeutics

5254_T_B-Cell_Mediated_Autoimmune_DDD (4)

Overcome the challenges in mapping the therapeutic target landscape for B-cell mediated autoimmune disease & T-cell dependent autoantibody responses with Duke University